共 50 条
- [31] Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Conte, Pier FrancoDieci, Maria VittoriaBisagni, GiancarloDe Laurentiis, MichelinoTondini, Carlo AlbertoSchmid, PeterDe Salvo, Gian LucaMoratello, GiacomoGuarneri, Valentina
- [32] Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology GroupBLOOD, 2015, 126 (23)Kelly, Kara M.Cole, Peter D.Chen, LuRoberts, Kenneth B.Hodgson, David C.McCarten, KathleenCho, Steve Y.Schwartz, Cindy
- [33] PHASE III STUDY OF RESPONSE ADAPTED THERAPY FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED VERY HIGH RISK HODGKIN LYMPHOMA (STAGES IIIB/IVB) (AHOD0831): A REPORT FROM THE CHILDREN'S ONCOLOGY GROUPHAEMATOLOGICA, 2016, 101 : 34 - 34Kelly, K.Cole, P. D.Chen, L.Roberts, K. B.Hodgson, D. C.McCarten, K.Cho, S. Y.Schwartz, C. L.
- [34] Initial safety results from a randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Cartwright, Thomas H.Thu-Cuc NguyenCohn, Allen LeeRichards, Donald A.
- [35] The ADEBAR-trial: Effect of participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) on treatment strategies and individual patient care in recruiting centersJOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 24S - 24SSommer, HJanni, WJRack, BSteinfeld, DSimon, WAugustin, DHeinrigs, MBismarck, FVHarbeck, NKiechle, M
- [36] Participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers: The ADEBAR-Trial.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 75S - 75SJanni, WSommer, HRack, BSteinfeld, DAugustin, DHeinrigs, MGauger, KKiechle, MHarbeck, NFriese, K
- [37] ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trialsJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Belldegrun, Arie S.Chamie, KarimKloepfer, PiaFall, BarbaraBevan, PaulStoerkel, StephanWilhelm, OlafPantuck, Allan J.
- [38] AN ASSESSMENT OF DTIC VERSUS LEVAMISOLE OR PLACEBO IN THE TREATMENT OF HIGH-RISK STAGE-I PATIENTS AFTER SURGICAL REMOVAL OF A PRIMARY MELANOMA OF THE SKIN - A PHASE-III ADJUVANT STUDY - EORTC PROTOCOL 18761EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 : S81 - S90LEJEUNE, FJMACHER, EKLEEBERG, URUMKE, PPRADE, MTHOMAS, DSUCIU, S
- [39] Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel-An analysis of final safety results.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Oudard, S.Latorzeff, I.Beuzeboc, P.Caty, A.Sevin, E.Delva, R.Rolland, F.Mourey, L.Priou, F.Culine, S.
- [40] ICON8B: GCIG PHASE III RANDOMISED TRIAL COMPARING WEEKLY DOSE-DENSE CHEMOTHERAPY plus BEVACIZUMAB TO THREE-WEEKLY CHEMOTHERAPY plus BEVACIZUMAB IN FIRST-LINE HIGH-RISK STAGE III-IV EPITHELIAL OVARIAN CANCER TREATMENT: PRIMARY PROGRESSION-FREE SURVIVAL ANALYSISINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A424 - A424Clamp, AndrewMcneish, IainLord, RosemaryHall, MarciaEssapen, SharadahCook, AudreyAgarwal, RoshanWalther, AxelBlagden, SarahO'Donnell, DearbhaileBrenton, James D.Sundar, SudhaSessa, CristianaCook, AdrianRadice, DomenicoSchiavone, FrancescaGentry-Maharaj, AleksandraKaplan, RichardParmar, Mahesh KbLedermann, Jonathan